


T-1101 tosylate

Chemical Properties

CAS No. :	2250404-95-4
Formula:	C ₃₁ H ₃₁ N ₅ O ₆ S ₃
Molecular Weight:	665.8
Storage:	Powder: -20°C for 3 years In solvent: -80°C for 1 year Actual storage temperature shall be subject to the COA.



Biological Description

Description	T-1101 tosylate (TAI-95 tosylate) is a Hec1/Nek2 inhibitor with antitumor activity.
Targets(IC50)	Apoptosis,MAPK,Microtubule Associated
In vitro	T-1101 has good oral absorption, along with potent in vitro antiproliferative activity (IC50: 14.8-21.5 nM).
In vivo	T-1101 tosylate can achieve high concentrations in Huh-7 and MDA-MB-231 tumor tissues, and showed promise in antitumor activity in mice bearing human tumor xenografts of liver cancer (Huh-7).
Animal Research	SCID mice bearing human Huh-7, BT-474, MCF-7, and MDA-MB-231 xenografts. Dosage: 25 mg/kg, 50 mg/kg. Oral administration; twice per day; 28 days

Solubility Information

Solubility	DMSO: 11 mg/mL (16.52 mM),Sonication is recommended. (< 1 mg/ml refers to the product slightly soluble or insoluble)
In vivo Formulation	10% DMSO+40% PEG300+5% Tween 80+45% Saline: 2 mg/mL (3 mM),Sonication is recommended. <i>Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions.</i>

Preparing Stock Solutions

	1mg	5mg	10mg
1 mM	1.502 mL	7.5098 mL	15.0195 mL
5 mM	0.3004 mL	1.502 mL	3.0039 mL
10 mM	0.1502 mL	0.751 mL	1.502 mL
50 mM	0.030 mL	0.1502 mL	0.3004 mL

Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents. Please use it as soon as possible.

Note: The dilution table applies only to solid products. For liquid products, please calculate the stock solution based on the stated concentration and/or density.

Reference

Chuang SH, et al. Discovery of T-1101 tosylate as a first-in-class clinical candidate for Hec1/Nek2 inhibition in cancer therapy. Eur J Med Chem. 2020 Apr 1;191:112118.

Inhibitor · Natural Compounds · Compound Libraries · Recombinant Proteins

This product is for Research Use Only · Not for Human or Veterinary or Therapeutic Use

Tel:781-999-4286 E_mail:info@targetmol.com Address:34 Washington Street,Wellesley Hills,MA 02481